GB202011126D0 - Use of cannabidiol in the treatment of sezures associated with mutifocal epilepsy - Google Patents
Use of cannabidiol in the treatment of sezures associated with mutifocal epilepsyInfo
- Publication number
- GB202011126D0 GB202011126D0 GBGB2011126.6A GB202011126A GB202011126D0 GB 202011126 D0 GB202011126 D0 GB 202011126D0 GB 202011126 A GB202011126 A GB 202011126A GB 202011126 D0 GB202011126 D0 GB 202011126D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- sezures
- mutifocal
- cannabidiol
- epilepsy
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/348—Cannabaceae
- A61K36/3482—Cannabis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2011126.6A GB2597284A (en) | 2020-07-20 | 2020-07-20 | Use of cannabidiol in the treatment of seizures associated with multifocal epilepsy |
| PCT/EP2021/069833 WO2022017925A1 (en) | 2020-07-20 | 2021-07-15 | Use of cannabidiol in the treatment of seizures associated with multifocal epilepsy syndrome |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2011126.6A GB2597284A (en) | 2020-07-20 | 2020-07-20 | Use of cannabidiol in the treatment of seizures associated with multifocal epilepsy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| GB202011126D0 true GB202011126D0 (en) | 2020-09-02 |
| GB2597284A GB2597284A (en) | 2022-01-26 |
Family
ID=72339066
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB2011126.6A Withdrawn GB2597284A (en) | 2020-07-20 | 2020-07-20 | Use of cannabidiol in the treatment of seizures associated with multifocal epilepsy |
Country Status (2)
| Country | Link |
|---|---|
| GB (1) | GB2597284A (en) |
| WO (1) | WO2022017925A1 (en) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201806953D0 (en) * | 2018-04-27 | 2018-06-13 | Gw Res Ltd | Cannabidiol Preparations |
-
2020
- 2020-07-20 GB GB2011126.6A patent/GB2597284A/en not_active Withdrawn
-
2021
- 2021-07-15 WO PCT/EP2021/069833 patent/WO2022017925A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022017925A1 (en) | 2022-01-27 |
| GB2597284A (en) | 2022-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB201900797D0 (en) | Use of cannabinoids in the treatment of comorbidities associated with epilepsy | |
| GB201902427D0 (en) | Use of cannabinoids in the treatment of epilepsy | |
| GB202014723D0 (en) | Use of cannabinoids in the treatment of epilepsy | |
| IL276217A (en) | Use of cannabinoids in the treatment of epilepsy | |
| GB2590793B (en) | Cannabidiol-C1 for use as a medicament and in the treatment of epilepsy | |
| GB201819573D0 (en) | Use of cannabinoids in the treatment of epilepsy | |
| GB202019301D0 (en) | Use of cannabidiol in the treatment of seizures associated with epilepsy syndromes | |
| IL274769A (en) | Use of cannabinoids in the treatment of epilepsy | |
| GB201907283D0 (en) | Use of cannabidiol in the treatment of epileptic spams | |
| GB2568809B (en) | Use of cannabinoids in the treatment of epilepsy | |
| GB2568471B (en) | Use of cannabinoids in the treatment of epilepsy | |
| GB201915522D0 (en) | Use of cannabidiol preparations in the treatment of absence epilepsy | |
| GB2564383B (en) | Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex | |
| GB201915519D0 (en) | Use of cannabidiol preparations in the treatment of temporal lobe epilepsy | |
| GB201912244D0 (en) | Use of cannabinoids in the treatment of dyskinesia associated with parkinson's disease | |
| GB2542155B (en) | Use of cannabidiol in the treatment of mental disorders | |
| GB202102010D0 (en) | Use of cannabidivarin in the treatment of seizures associated with canine epilepsy | |
| GB201510664D0 (en) | Use of cannabinoids in the treatment of epilepsy | |
| IL286334A (en) | Modified micrornas and their use in the treatment of cancer | |
| IL289371A (en) | Methylthioninium for use in the treatment of synaptopathies | |
| GB202108690D0 (en) | Use of cannabinoids in the treatment of epilepsy | |
| IL274838A (en) | Use of mir101 or mir128 in the treatment of seizure disorders | |
| PL3040329T3 (en) | Aromatic compound and use thereof in the treatment of disorders associated with bone metabolism | |
| SI3914247T1 (en) | Use of migalostat in reducing the risk of cerebrovascular event in patients with fabry disease | |
| GB202011126D0 (en) | Use of cannabidiol in the treatment of sezures associated with mutifocal epilepsy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |